| Dictionary, Encyclopedia and Thesaurus - The Free Dictionary 1,507,063,403 visitors served. |
|
Dictionary/ thesaurus | Medical dictionary | Legal dictionary | Financial dictionary | Acronyms | Idioms | Encyclopedia | Wikipedia encyclopedia | ? |
erythropoietin |
Also found in: Wikipedia, Hutchinson | 0.15 sec. |
|
erythropoietin /eryth·ro·poi·e·tin/ (-poi´ĕ-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production (erythropoiesis). recombinant human erythropoietin (r-HuEPO) epoetin.
Erythropoietin A hormone produced by the kidneys that stimulates the production of red blood cells by bone marrow. Mentioned in: Dialysis, Kidney erythropoietin (EPO) [erith′rōpō·ē′tin] Etymology: Gk, erythros + poiein, to make a glycoprotein hormone synthesized mainly in the kidneys and released into the bloodstream in response to anoxia. The hormone acts to stimulate and to regulate the production of erythrocytes and thus increases the oxygen-carrying capacity of the blood. See also erythropoiesis. erythropoietin a glycoprotein hormone secreted mainly by the kidney. A profactor, erythropoietinogen, is first produced in the liver, transferred to the kidney and converted to active erythropoietin in the kidney. The erythropoietin acts on stem cells of the bone marrow to stimulate red blood cell production (erythropoiesis). Called also erythropoietin stimulating factor, erythrogenin. recombinant erythropoietin used to treat dogs and cats with nonregenerative anemia of renal disease; animals develop antibodies to the human product. erythropoietin stimulating factor see erythropoietin (above). erythropoietin EPO Physiology A 46 kD glycoprotein colony-stimulating factor produced predominantly by cells adjacent to the proximal renal tubules in response to signals from an oxygen-sensitive substances in the kidneys–eg, heme
Adverse effects Chest pain, swelling, tachycardia, headache, HTN; erythropoietin–EP binds to receptors in erythroid precursors that mature into RBCs; EP is ↑ by hypoxia or by ectopic production from tumors–eg, cerebellar
hemangioblastoma, hepatoma, pheochromocytoma, uterine leiomyoma, and renal cell carcinoma; it may not be ↑ in anemic premature infants, and is ↓ in 2º anemia, chronic inflammation, P vera, and certain CAs and may be useful in
myeloma-related anemia; EP therapy is indicated for HIV-related anemia, anemia of renal failure and prematurity; it ↑ number of units of autologous RBCs that may be donated before surgery, for ↑ number of units that may be phlebotomized in
Pts with hemochromatosis and to ↑ units that may be drawn from a person with a rare blood type How to thank TFD for its existence? Tell a friend about us, add a link to this page, add the site to iGoogle, or visit webmaster's page for free fun content. |
|
| ? Mentioned in | ? References in periodicals archive | |
|---|---|---|
The suit was filed in 1995 and claimed that Ortho Biotech, a Johnson & Johnson subsidiary, breached its license rights by improperly making sales of erythropoetin, known as EPO, into Amgen's exclusive dialysis market. The authors found that treatment of these patients with Erythropoetin significantly improved the symptoms of these patients. EPO, short for erythropoetin, was created by Amgen in the early 1980s and is now one the top selling drugs in the world. |
| Medical Dictionary |
| Free Tools: |
For surfers:
Browser extension |
Word of the Day |
Help
For webmasters: Free content | Linking | Lookup box | Double-click lookup | Partner with us |
|---|